• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study.每周一次双倍剂量的依那西普治疗幼年特发性关节炎患者的疗效：一项临床研究。
Ann Rheum Dis. 2007 May;66(5):704-5. doi: 10.1136/ard.2006.067629. Epub 2007 Feb 26.
2
Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.
Rheumatol Int. 2008 Feb;28(4):397-8, author reply 399. doi: 10.1007/s00296-007-0468-5. Epub 2007 Oct 17.
3
Juvenile idiopathic arthritis: current and future treatment options.青少年特发性关节炎：当前及未来的治疗选择
Expert Opin Pharmacother. 2006 Mar;7(4):387-99. doi: 10.1517/14656566.7.4.387.
4
Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis.治疗全身型幼年类风湿性关节炎-幼年特发性关节炎的临床试验。
Curr Rheumatol Rep. 2000 Aug;2(4):313-5. doi: 10.1007/s11926-000-0068-9.
5
Recalcitrant hand pompholyx: variable response to etanercept.
Clin Exp Dermatol. 2006 Jan;31(1):145-6. doi: 10.1111/j.1365-2230.2005.01947.x.
6
Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis.每周一次应用依那西普治疗幼年特发性关节炎患儿的安全性和有效性。
Rheumatol Int. 2007 Dec;28(2):153-6. doi: 10.1007/s00296-007-0399-1. Epub 2007 Jul 20.
7
A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
Health Technol Assess. 2002;6(17):1-43. doi: 10.3310/hta6170.
8
Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.依那西普在特定类型幼年特发性关节炎儿童中的长期安全性和有效性。
Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.
9
[Recent topics on rheumatism and collagen diseases in childhood].[儿童风湿性疾病和胶原病的近期话题]
Nihon Naika Gakkai Zasshi. 2007 Oct 10;96(10):2226-34. doi: 10.2169/naika.96.2226.
10
Treatment of psoriatic arthritis with etanercept.用依那西普治疗银屑病关节炎。
J Am Acad Dermatol. 2001 Jun;44(6):1052. doi: 10.1067/mjd.2001.112353.

引用本文的文献

1
Treatment in juvenile rheumatoid arthritis and new treatment options.青少年类风湿性关节炎的治疗及新的治疗选择。
Turk Pediatri Ars. 2015 Mar 1;50(1):1-10. doi: 10.5152/tpa.2015.2229. eCollection 2015 Mar.
2
The development and assessment of biological treatments for children.儿童生物治疗的开发与评估。
Br J Clin Pharmacol. 2015 Mar;79(3):379-94. doi: 10.1111/bcp.12406.
3
Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.肿瘤坏死因子抑制剂在幼年特发性关节炎治疗中的应用：循证评价。
Paediatr Drugs. 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610-000000000-00000.
4
[Juvenile arthritides].[青少年关节炎]
Z Rheumatol. 2010 Oct;69(8):719-35; quiz 736-7. doi: 10.1007/s00393-010-0664-7.
5
Challenges in the management of juvenile idiopathic arthritis with etanercept.使用依那西普治疗青少年特发性关节炎的管理挑战。
Biologics. 2009;3:127-39. Epub 2009 Jul 13.
6
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.治疗幼年特发性关节炎的生物疗法：来自成人和儿童治疗经验的启示。
Biologics. 2008 Jun;2(2):229-52. doi: 10.2147/btt.s2210.
7
Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.
Rheumatol Int. 2008 Feb;28(4):397-8, author reply 399. doi: 10.1007/s00296-007-0468-5. Epub 2007 Oct 17.

本文引用的文献

1
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.对于强直性脊柱炎患者，依那西普每周一次50毫克与每周两次25毫克的疗效相当。
Ann Rheum Dis. 2006 Dec;65(12):1572-7. doi: 10.1136/ard.2006.056747. Epub 2006 Sep 12.
2
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.依那西普治疗多关节型幼年类风湿关节炎患儿的长期安全性和有效性
Arthritis Rheum. 2006 Jun;54(6):1987-94. doi: 10.1002/art.21885.
3
Current management of juvenile idiopathic arthritis.青少年特发性关节炎的当前管理
Best Pract Res Clin Rheumatol. 2006 Apr;20(2):279-300. doi: 10.1016/j.berh.2005.11.008.
4
Patterns of clinical remission in select categories of juvenile idiopathic arthritis.特定类型青少年特发性关节炎的临床缓解模式。
Arthritis Rheum. 2005 Nov;52(11):3554-62. doi: 10.1002/art.21389.
5
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.幼年类风湿关节炎患儿中依那西普时间-浓度曲线的群体药代动力学分析与模拟
J Clin Pharmacol. 2005 Mar;45(3):246-56. doi: 10.1177/0091270004271945.
6
The German etanercept registry for treatment of juvenile idiopathic arthritis.德国依那西普治疗幼年特发性关节炎登记系统。
Ann Rheum Dis. 2004 Dec;63(12):1638-44. doi: 10.1136/ard.2003.014886. Epub 2004 Apr 28.
7
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.活动性类风湿关节炎患者每周一次注射50毫克依那西普：一项多中心、随机、双盲、安慰剂对照试验的结果。
Arthritis Rheum. 2004 Feb;50(2):353-63. doi: 10.1002/art.20019.
8
Preliminary definition of disease flare in juvenile rheumatoid arthritis.
J Rheumatol. 2002 May;29(5):1058-64.
9
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.依那西普治疗多关节型幼年类风湿关节炎患儿。儿科风湿病协作研究组。
N Engl J Med. 2000 Mar 16;342(11):763-9. doi: 10.1056/NEJM200003163421103.
10
Preliminary definition of improvement in juvenile arthritis.青少年关节炎改善的初步定义。
Arthritis Rheum. 1997 Jul;40(7):1202-9. doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R.

Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study.

作者信息

Prince Femke H M, Twilt Marinka, Jansen-Wijngaarden Nelleke C J A, van Suijlekom-Smit Lisette W A

出版信息

Ann Rheum Dis. 2007 May;66(5):704-5. doi: 10.1136/ard.2006.067629. Epub 2007 Feb 26.

DOI:10.1136/ard.2006.067629
PMID:17324973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1954640/
Abstract
摘要